Saltar al contenido
Merck

1344702

USP

Iopamidol

United States Pharmacopeia (USP) Reference Standard

Sinónimos:

(S)-N,N′-Bis[2-hydroxy-1-(hydroxymethyl)ethyl]-2,4,6-triiodo-5-lactamidoisophthalamide

Slide 1 of 1
Iniciar sesión para ver los precios por organización y contrato.

Seleccione un Tamaño

En este momento no podemos mostrarle ni los precios ni la disponibilidad

Acerca de este artículo

Fórmula empírica (notación de Hill):
C17H22I3N3O8
Número CAS:
60166-93-0
Peso molecular:
777.09
MDL number:
MFCD00867931
UNSPSC Code:
41116107
NACRES:
NA.24

Documentos clave

Ver Toda la documentación

Saltar a

Servicio técnico
¿Necesita ayuda? Nuestro equipo de científicos experimentados está aquí para ayudarle.
Permítanos ayudarle

grade

pharmaceutical primary standard

API family

iopamidol

manufacturer/tradename

USP

application(s)

pharmaceutical (small molecule)

format

neat

SMILES string

Ic1c(c(c(c(c1C(=O)NC(CO)CO)I)C(=O)NC(CO)CO)I)NC(=O)[C@@H](O)C

InChI

1S/C17H22I3N3O8/c1-6(28)15(29)23-14-12(19)9(16(30)21-7(2-24)3-25)11(18)10(13(14)20)17(31)22-8(4-26)5-27/h6-8,24-28H,2-5H2,1H3,(H,21,30)(H,22,31)(H,23,29)/t6-/m0/s1

InChI key

XQZXYNRDCRIARQ-LURJTMIESA-N

¿Está buscando productos similares? Visita Guía de comparación de productos

Categorías relacionadas

Comparar elementos similares

Ver comparación completa

Mostrar Diferencias

1 of 4

Este artículo
I03290001344724PHR1985
USP

USP

1344702

Iopamidol

vibrant-m

I0329000

Iopamidol

USP

USP

1344724

Iopamidol Related Compound A

Iopamidol Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1985

Iopamidol

grade

pharmaceutical primary standard

grade

pharmaceutical primary standard

grade

pharmaceutical primary standard

grade

certified reference material, pharmaceutical secondary standard

manufacturer/tradename

USP

manufacturer/tradename

EDQM

manufacturer/tradename

USP

manufacturer/tradename

-

format

neat

format

neat

format

neat

format

-

application(s)

pharmaceutical (small molecule)

application(s)

pharmaceutical (small molecule)

application(s)

pharmaceutical (small molecule)

application(s)

pharmaceutical

API family

iopamidol

API family

iopamidol

API family

iopamidol

API family

-

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Iopamidol USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
  • Iopamidol Injection

Analysis Note

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Other Notes

Sales restrictions may apply.

comparable product

Referencia del producto
Descripción
Precios

related product

Referencia del producto
Descripción
Precios

Clase de almacenamiento

11 - Combustible Solids

flash_point_f

Not applicable

flash_point_c

Not applicable

Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documentos section.

Si necesita más asistencia, póngase en contacto con Atención al cliente

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Tomonori Kanda et al.
PloS one, 10(2), e0118317-e0118317 (2015-02-24)
Double hypoglossal canal, namely a hypoglossal canal bridging, is a normal variation of the hypoglossal canal. Racial differences in the prevalence of double hypoglossal canal have been reported. We evaluated the prevalence of double hypoglossal canal in a Japanese population
Kiyoko Yoshino et al.
Hepatology research : the official journal of the Japan Society of Hepatology, 44(11), 1088-1094 (2013-09-17)
Although rupture of rectal varices is rarely encountered, it may provoke massive and fatal hemorrhage in patients with liver cirrhosis. We examined the clinical features of patients showing bleeding from rectal varices to establish a suitable therapeutic strategy for the
Shigeo Horinaka et al.
Atherosclerosis, 235(1), 239-245 (2014-05-28)
The cardio-ankle vascular index (CAVI) is an arterial stiffness index based on the stiffness parameter β, which is essentially independent of blood pressure. The objective of this study was to determine whether CAVI correlates with the regional stiffness parameter β
Karla Maria Treitl et al.
Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists, 22(1), 63-70 (2015-03-17)
To prospectively assess current limitations and complication rates of the transbrachial access technique for endovascular treatment of peripheral vascular pathologies. In total, 150 patients (112 men; mean age 66.3 ± 10.0 years) with arterial occlusive disease underwent endovascular therapy via
Fereshteh Hajsadeghi et al.
Atherosclerosis, 237(2), 486-489 (2014-12-03)
Increased-epicardial-adipose tissue (EAT) is associated with the presence and severity of subclinical-atherosclerosis. This study investigates the long-term clinical-outcome of subjects with and without increased-EAT. Two hundred and forty-five subjects, aged 61 ± 9 years and 34% women underwent clinically-indicated computed-tomography-angiography
Ver todos los artículos relacionados

Preguntas

Revisiones

Sin puntuación

Filtros activos

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico